Search Results - Saremi, Aramesh

Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT) by Saremi, Aramesh, Bahn, Gideon, Reaven, Peter D.

Get full text Get full text Get full text

A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT) by Saremi, Aramesh, Bahn, Gideon D., Reaven, Peter D.

Get full text Get full text Get full text

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial by Giorgino, Francesco, Shaunik, Alka, Liu, Minzhi, Saremi, Aramesh

Get full text Get full text Get full text

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT) by Koska, Juraj, Saremi, Aramesh, Bahn, Gideon, Yamashita, Shizuya, Reaven, Peter D.

Get full text Get full text Get full text

Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration... by Gautier, Thibault, Silwal, Rupesh, Saremi, Aramesh, Boss, Anders, Breton, Marc D.

Get full text Get full text Get full text

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L by Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Get full text Get full text Get full text

Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L by Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Get full text Get full text Get full text

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L by Blonde, Lawrence, Berard, Lori, Saremi, Aramesh, Huang, Yao, Aroda, Vanita R., Raccah, Denis

Get full text Get full text Get full text

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial by Saremi, Aramesh, Schwenke, Dawn C., Bahn, Gideon, Ge, Ling, Emanuele, Nicholas, Reaven, Peter D.

Get full text Get full text Get full text

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study by Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D.

Get full text Get full text Get full text

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study by Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco

Get full text Get full text Get full text

Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT) by Saremi, Aramesh, Moritz, Thomas E., Anderson, Robert J., Abraira, Carlos, Duckworth, William C., Reaven, Peter D.

Get full text Get full text Get full text

Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance by Hu, Xia, Reaven, Peter D., Saremi, Aramesh, Liu, Ninghao, Abbasi, Mohammad Ali, Liu, Huan, Migrino, Raymond Q.

Get full text Get full text Get full text

Association Between IL-6 and the extent of Coronary Atherosclerosis in The Veterans Affairs Diabetes Trial (VADT) by Saremi, Aramesh, Anderson, Robert J., Luo, Ping, Moritz, Thomas E., Schwenke, Dawn C., Allison, Mathew, Reaven, Peter D.

Get full text Get full text Get full text

Quantification of LVEF≤35% misclassification by 2D-echocardiography as compared to cardiac magnetic resonance in coronary artery disease: implications for AICD therapy by Parrington, Diane J, Saremi, Aramesh, Girotra, Sudhakar V, Dev, Sandesh, Oh, Charles, Scott, Cynthia L, Migrino, Raymond Q

Get full text Get full text

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes by Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D.

Get full text Get full text Get full text

Hepatic Fat and Inflammation in Type 2 Diabetes by Saremi, Aramesh, Allison, Matthew, Ditomasso, Dominic, Ge, Ling, Anderson, Robert, Moritz, Tom E., Duckworth, William, Abraira, Carlos, Reaven, Peter D.

Get full text Get full text Get full text

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... by Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.

Get full text Get full text Get full text

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Explorat... by Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio

Get full text Get full text Get full text

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors by Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.

Get full text Get full text Get full text